Logo image of KIN.BR

KINEPOLIS (KIN.BR) Stock Fundamental Analysis

Europe - EBR:KIN - BE0974274061 - Common Stock

30.7 EUR
-0.1 (-0.32%)
Last: 10/16/2025, 7:00:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to KIN. KIN was compared to 45 industry peers in the Entertainment industry. KIN has a medium profitability rating, but doesn't score so well on its financial health evaluation. KIN scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

KIN had positive earnings in the past year.
KIN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KIN reported negative net income in multiple years.
Of the past 5 years KIN 4 years had a positive operating cash flow.
KIN.BR Yearly Net Income VS EBIT VS OCF VS FCFKIN.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

KIN's Return On Assets of 4.54% is fine compared to the rest of the industry. KIN outperforms 66.67% of its industry peers.
KIN has a better Return On Equity (23.61%) than 84.44% of its industry peers.
KIN has a Return On Invested Capital of 8.28%. This is in the better half of the industry: KIN outperforms 73.33% of its industry peers.
The Average Return On Invested Capital over the past 3 years for KIN is below the industry average of 10.91%.
The 3 year average ROIC (6.76%) for KIN is below the current ROIC(8.28%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.54%
ROE 23.61%
ROIC 8.28%
ROA(3y)3.57%
ROA(5y)0.53%
ROE(3y)21.42%
ROE(5y)-2.24%
ROIC(3y)6.76%
ROIC(5y)N/A
KIN.BR Yearly ROA, ROE, ROICKIN.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

KIN's Profit Margin of 7.98% is fine compared to the rest of the industry. KIN outperforms 75.56% of its industry peers.
In the last couple of years the Profit Margin of KIN has declined.
Looking at the Operating Margin, with a value of 15.19%, KIN belongs to the top of the industry, outperforming 84.44% of the companies in the same industry.
In the last couple of years the Operating Margin of KIN has declined.
KIN's Gross Margin of 24.54% is on the low side compared to the rest of the industry. KIN is outperformed by 86.67% of its industry peers.
KIN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 15.19%
PM (TTM) 7.98%
GM 24.54%
OM growth 3YN/A
OM growth 5Y-4.79%
PM growth 3YN/A
PM growth 5Y-6.62%
GM growth 3Y115.73%
GM growth 5Y-3.42%
KIN.BR Yearly Profit, Operating, Gross MarginsKIN.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), KIN is creating some value.
KIN has about the same amout of shares outstanding than it did 1 year ago.
KIN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, KIN has an improved debt to assets ratio.
KIN.BR Yearly Shares OutstandingKIN.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
KIN.BR Yearly Total Debt VS Total AssetsKIN.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 1.56, we must say that KIN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.56, KIN is in line with its industry, outperforming 60.00% of the companies in the same industry.
The Debt to FCF ratio of KIN is 5.38, which is a neutral value as it means it would take KIN, 5.38 years of fcf income to pay off all of its debts.
KIN has a Debt to FCF ratio (5.38) which is in line with its industry peers.
A Debt/Equity ratio of 2.87 is on the high side and indicates that KIN has dependencies on debt financing.
KIN has a Debt to Equity ratio of 2.87. This is in the lower half of the industry: KIN underperforms 71.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF 5.38
Altman-Z 1.56
ROIC/WACC1.46
WACC5.68%
KIN.BR Yearly LT Debt VS Equity VS FCFKIN.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

KIN has a Current Ratio of 0.47. This is a bad value and indicates that KIN is not financially healthy enough and could expect problems in meeting its short term obligations.
KIN has a worse Current ratio (0.47) than 88.89% of its industry peers.
A Quick Ratio of 0.44 indicates that KIN may have some problems paying its short term obligations.
KIN has a worse Quick ratio (0.44) than 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.44
KIN.BR Yearly Current Assets VS Current LiabilitesKIN.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.32% over the past year.
Measured over the past years, KIN shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.80% on average per year.
The Revenue has been growing slightly by 5.38% in the past year.
Measured over the past years, KIN shows a small growth in Revenue. The Revenue has been growing by 0.95% on average per year.
EPS 1Y (TTM)34.32%
EPS 3YN/A
EPS 5Y-5.8%
EPS Q2Q%5581.82%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y29.47%
Revenue growth 5Y0.95%
Sales Q2Q%6.22%

3.2 Future

Based on estimates for the next years, KIN will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.39% on average per year.
The Revenue is expected to grow by 4.98% on average over the next years.
EPS Next Y31.93%
EPS Next 2Y25.05%
EPS Next 3Y20.22%
EPS Next 5Y14.39%
Revenue Next Year4.68%
Revenue Next 2Y5.5%
Revenue Next 3Y5.08%
Revenue Next 5Y4.98%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KIN.BR Yearly Revenue VS EstimatesKIN.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
KIN.BR Yearly EPS VS EstimatesKIN.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2

7

4. Valuation

4.1 Price/Earnings Ratio

KIN is valuated rather expensively with a Price/Earnings ratio of 17.95.
Compared to the rest of the industry, the Price/Earnings ratio of KIN indicates a rather cheap valuation: KIN is cheaper than 88.89% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of KIN to the average of the S&P500 Index (27.31), we can say KIN is valued slightly cheaper.
A Price/Forward Earnings ratio of 11.71 indicates a reasonable valuation of KIN.
Based on the Price/Forward Earnings ratio, KIN is valued cheaper than 84.44% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.85. KIN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 17.95
Fwd PE 11.71
KIN.BR Price Earnings VS Forward Price EarningsKIN.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, KIN is valued a bit cheaper than 62.22% of the companies in the same industry.
86.67% of the companies in the same industry are more expensive than KIN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 6.43
EV/EBITDA 8.64
KIN.BR Per share dataKIN.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KIN's earnings are expected to grow with 20.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y25.05%
EPS Next 3Y20.22%

3

5. Dividend

5.1 Amount

KIN has a Yearly Dividend Yield of 1.25%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.19, KIN pays a bit more dividend than its industry peers.
With a Dividend Yield of 1.25, KIN pays less dividend than the S&P500 average, which is at 2.40.
Industry RankSector Rank
Dividend Yield 1.25%

5.2 History

The dividend of KIN decreases each year by -3.32%.
Dividend Growth(5Y)-3.32%
Div Incr Years1
Div Non Decr Years2
KIN.BR Yearly Dividends per shareKIN.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

KIN pays out 31.09% of its income as dividend. This is a sustainable payout ratio.
DP31.09%
EPS Next 2Y25.05%
EPS Next 3Y20.22%
KIN.BR Yearly Income VS Free CF VS DividendKIN.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M
KIN.BR Dividend Payout.KIN.BR Dividend Payout, showing the Payout Ratio.KIN.BR Dividend Payout.PayoutRetained Earnings

KINEPOLIS

EBR:KIN (10/16/2025, 7:00:00 PM)

30.7

-0.1 (-0.32%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)08-21 2025-08-21
Earnings (Next)N/A N/A
Inst Owners18%
Inst Owner ChangeN/A
Ins Owners1.8%
Ins Owner ChangeN/A
Market Cap840.26M
Analysts86
Price Target49.47 (61.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.25%
Yearly Dividend0.54
Dividend Growth(5Y)-3.32%
DP31.09%
Div Incr Years1
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.21%
PT rev (3m)-2.02%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.03%
EPS NY rev (3m)-11.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.16%
Valuation
Industry RankSector Rank
PE 17.95
Fwd PE 11.71
P/S 1.42
P/FCF 6.43
P/OCF 4.84
P/B 4.19
P/tB 37.49
EV/EBITDA 8.64
EPS(TTM)1.71
EY5.57%
EPS(NY)2.62
Fwd EY8.54%
FCF(TTM)4.77
FCFY15.54%
OCF(TTM)6.34
OCFY20.65%
SpS21.68
BVpS7.32
TBVpS0.82
PEG (NY)0.56
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.54%
ROE 23.61%
ROCE 11.27%
ROIC 8.28%
ROICexc 8.93%
ROICexgc 11.76%
OM 15.19%
PM (TTM) 7.98%
GM 24.54%
FCFM 22.02%
ROA(3y)3.57%
ROA(5y)0.53%
ROE(3y)21.42%
ROE(5y)-2.24%
ROIC(3y)6.76%
ROIC(5y)N/A
ROICexc(3y)7.02%
ROICexc(5y)N/A
ROICexgc(3y)8.91%
ROICexgc(5y)N/A
ROCE(3y)9.19%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-1%
ROICexc growth 3YN/A
ROICexc growth 5Y-1.69%
OM growth 3YN/A
OM growth 5Y-4.79%
PM growth 3YN/A
PM growth 5Y-6.62%
GM growth 3Y115.73%
GM growth 5Y-3.42%
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF 5.38
Debt/EBITDA 3.35
Cap/Depr 52.23%
Cap/Sales 7.23%
Interest Coverage 4.1
Cash Conversion 100.75%
Profit Quality 276.05%
Current Ratio 0.47
Quick Ratio 0.44
Altman-Z 1.56
F-Score8
WACC5.68%
ROIC/WACC1.46
Cap/Depr(3y)43.12%
Cap/Depr(5y)41.32%
Cap/Sales(3y)6.29%
Cap/Sales(5y)10.19%
Profit Quality(3y)301.12%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.32%
EPS 3YN/A
EPS 5Y-5.8%
EPS Q2Q%5581.82%
EPS Next Y31.93%
EPS Next 2Y25.05%
EPS Next 3Y20.22%
EPS Next 5Y14.39%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y29.47%
Revenue growth 5Y0.95%
Sales Q2Q%6.22%
Revenue Next Year4.68%
Revenue Next 2Y5.5%
Revenue Next 3Y5.08%
Revenue Next 5Y4.98%
EBIT growth 1Y16.5%
EBIT growth 3YN/A
EBIT growth 5Y-3.89%
EBIT Next Year106.02%
EBIT Next 3Y31.28%
EBIT Next 5Y22.36%
FCF growth 1Y30.27%
FCF growth 3Y19%
FCF growth 5Y6.53%
OCF growth 1Y26.43%
OCF growth 3Y22.57%
OCF growth 5Y1.63%